Active substancePilocarpinePilocarpine Similar drugsTo uncover Pilocarpine drops d / eye MOSCOW ENDOCRINE FACTORY, FSUE Russia Pilocarpine drops d / eye TATHIMFARMPREPARATY, JSC Russia Pilocarpine drops d / eye FARMAK, PAO Ukraine Pilocarpine drops d / eye UPDATE OF PFC, CJSC Russia Pilocarpine-DIA drops d / eye DIAPHARM Institute of Molecular Diagnostics, ZAO Russia Pilocarpine-Ferein® drops d / eye BRYNTSALOV-A, CJSC Russia Dosage form: & nbspEye Drops Composition:1 ml of the solution contains pilocarpine hydrochloride 10 mg;Excipients: Boric acid - 19 mg, water for injection up to 1 ml. Description:Transparent colorless liquid. Pharmacotherapeutic group:The antiglaucoma is m-holinomimetic. ATX: & nbspS.01.E.B.01 Pilocarpine Pharmacodynamics:Pilocarpine refers to m-cholinomimetic agents. The mechanism of action is due to the excitation of peripheral m-cholinergic receptors, which causes a reduction in the circumference of the muscle of the iris and ciliary muscle, is accompanied by a narrowing of the pupil and an expansion of the angle of the anterior chamber of the eye, an improvement in the outflow of the intraocular fluid. With primary open-angle glaucoma, instillation of 1% solution causes a decrease in intraocular pressure by 25-26%. The onset of the effect - after 30-40 minutes, reaches a maximum after 1.5-2 hours and lasts for 4-14 hours. Pharmacokinetics:Pilocarpine well penetrates through the cornea.In the conjunctival sac is almost not absorbed. The time to reach the maximum concentration (TCam) in the aqueous humor is 30 min. It is retained in the tissues of the eye, which increases its half-life from the eye tissues (T1 / 2), which is 1.5-2.5 hours. It is excreted unchanged with intraocular fluid. Partially penetrates into the blood plasma and is inactivated by hydrolysis in blood serum and liver. Indications:Acute attack of closed-angle glaucoma, secondary glaucoma (vascular, post-traumatic (burns)), primary open-angle glaucoma (in combination with beta-blockers or other medications that reduce intraocular pressure). The need to narrow the pupil after instillation midriatikov. Contraindications:Hypersensitivity to the components of the drug. Irit, iridocyclitis, iridocyclic crisis, uveitis, cyclitis, keratitis and other eye diseases, in which the narrowing of the pupil is undesirable (after surgical interventions on the eye to prevent the appearance of posterior synechia). Bronchial asthma.Pregnancy, the period of breastfeeding, the age of 18 years. Carefully:Use with caution in patients with retinal detachment in history and in young patients with high degree of myopia. Pregnancy and lactation:The drug is contraindicated for use during pregnancy. If it is necessary to prescribe the drug during lactation, breastfeeding should be discontinued. Dosing and Administration:When primary glaucoma is instilled in each eye for 1-2 drops - 2-4 times a day, the daily dose, as well as the duration of treatment are determined by the doctor, depending on the level of intraocular pressure. If necessary, the drug can be combined with β-blockers. At an acute attack of an angle-closure glaucoma Pilocarpine appoint: during the first hour - every 15 minutes for 1 drop; for 2-3 hours - every 30 minutes for 1 drop; for 4-6 hours - every 60 minutes for 1 drop; further 3-6 times a day before stopping the attack. Side effects:During the application of Pilocarpine may develop: - Local side effects: miosis, short-term pain in the eye, its redness, decreased visual acuity, as a result of persistent miosis (at night), spasm of accommodation, headache in the temples and paraorbital regions, superficial keratitis, increased lacrimation, allergic conjunctivitis. With prolonged use, it is possible to develop follicular conjunctivitis, contact eyelid dermatitis, retinal detachment, nuclear cataract, endothelium edema of optic discs, corneal keratopathy, reversible lens opacity. Possible systemic side effects: bronchospasm, headache, hypersalivation, pulmonary edema, increased blood pressure, nausea, vomiting, diarrhea. Overdose:In case of an overdose, the following symptoms are observed: nausea, bradycardia, persistent miosis, pain in the eyes, visual impairment, headache. At casual reception inward the bronchospasm, cardiovascular failure can develop.Treatment: symptomatic. Cancel the drug, with severe bradycardia, administer 0.5-2 mg of atropine parenterally. Interaction:Atropine and other M-holinoblokatory are pilocarpine antagonists. With simultaneous use with adrenomimetics, antagonism of action (effect on the diameter of the pupil) can be observed.Timolol and phenylephrine increase the decrease in intraocular pressure.It is possible to use pilocarpine in combination with β-adrenoblockers, inhibitors of carbonic anhydrase.M-cholinomimetic action of pilocarpine decreases with combination with tricyclic antidepressants, phenothiazine derivatives, chlorprotixen, clozapine; is enhanced by cholinesterase inhibitors.There may be a bradycardia and a decrease in blood pressure during general anesthesia with the use of halothane (in patients who use Pilocarpine in the eye drops). Special instructions:Immediately before use, you should hold the vial with the drug in the palm of your hand to warm it to body temperature. The cap is unscrewed, removed and, slightly pressing on the body of the vial, a solution is injected into the eye. After instillation the cap is tightly screwed.Treatment should be performed with regular monitoring of intraocular pressure.To reduce absorption to the systemic blood stream, it is recommended to squeeze the tear ducts after 1-2 minutes, pressing the finger at the inner corner of the eye in the area of the projection of the lacrimal sac.The use of pilocarpine is not recommended when wearing soft contact lenses.In the presence of an initial cataract, the myotic effect can cause a transient deterioration of vision (sensation of nearsightedness),therefore, during the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions. Effect on the ability to drive transp. cf. and fur:Care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased attention and speed of psychomotor reactions. Form release / dosage:Eye drops 1%. Packaging:For 5 ml or 10 ml in polyethylene bottles, ukuporennye caps.Each bottle, along with instructions for medical use, is put in a pack of cardboard. Storage conditions:Store in a dark place at a temperature of 8 ° C to 15 ° C.Keep out of the reach of children. Shelf life:3 years. After opening the bottle, the drug is suitable for 28 days.Do not use after the expiration date printed on the package. Terms of leave from pharmacies:On prescription Registration number:П N015742 / 01 Date of registration:21.05.2009 The owner of the registration certificate:FARMAK, PAO FARMAK, PAO Ukraine Manufacturer: & nbspFARMAK, PAO Ukraine Representation: & nbspFARMAK PAOFARMAK PAO Information update date: & nbsp28.07.2014 Illustrated instructions × Illustrated instructions Instructions